Stockscreener 앱 받기
3.4569
2.06%
0.0669
전일 마감가:
$3.39
열려 있는:
$3.37
하루 거래량:
401.82K
Relative Volume:
0.23
시가총액:
$338.15M
수익:
$40.52M
순이익/손실:
$-160.06M
주가수익비율:
-1.8355
EPS:
-1.8834
순현금흐름:
$-165.85M
1주 성능:
+25.36%
1개월 성능:
+41.80%
6개월 성능:
-14.78%
1년 성능:
+156.30%
1일 변동 폭
$3.37
$3.575
1주일 범위
$2.71
$3.575
52주 변동 폭
$1.23
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.455 | 331.79M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
441.04 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.48 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
845.48 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.68 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.27 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell - MarketBeat
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine, Inc. Files Form 8-K Announcing Changes in Certifying Accountant – April 2026 - Minichart
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young - Investing.com India
Editas Medicine appoints PwC as new auditor, dismisses Ernst & Young By Investing.com - Investing.com South Africa
Audit shakeup at Editas Medicine (NASDAQ: EDIT) as PwC replaces Ernst & Young - Stock Titan
Growth Value: How correlated is Editas Medicine Inc to the S P500Sell Signal & Safe Capital Investment Plans - baoquankhu1.vn
Price Action: Will Editas Medicine Inc benefit from sector rotation2026 Trade Ideas & Weekly High Conviction Ideas - baoquankhu1.vn
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
EDIT Should I Buy - Intellectia AI
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Eastern Progress
Volume Report: Can Editas Medicine Inc ride the EV waveGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Editas Medicine Inc Stock: Genome Editing Pioneer Faces Key Milestones in Competitive Biotech Landsc - AD HOC NEWS
Fundamentals Check: Will Editas Medicine Inc benefit from sector rotationGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Setup Watch: Does Editas Medicine Inc have strong fundamentals2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program - MSN
EDIT PE Ratio & Valuation, Is EDIT Overvalued - Intellectia AI
Editas Medicine Inc Stock: Gene Editing Pioneer Faces Clinical and Market Hurdles in Biotechnology L - AD HOC NEWS
Editas Medicine wins CRISPR patent ruling from USPTO - StreetInsider
USPTO Ruling Impacts Editas Medicine CRISPR IP Position - TipRanks
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - Bitget
USPTO Reaffirms Broad Institute’s Patents in CRISPR/Cas9 Dispute - geneonline.com
CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate - Stock Titan
[SCHEDULE 13G/A] Editas Medicine, Inc. Amended Passive Investment Disclosure - Stock Titan
EDITAS MEDICINE Operating Margin %: -56.65% | Fairly Valued - GuruFocus
MACD Signal: Can Editas Medicine Inc maintain sales growthEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
How correlated is Editas Medicine Inc to the S P5002026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Q2 EPS Estimates for Editas Medicine Decreased by Analyst - MarketBeat
Zacks Research Weighs in on Editas Medicine FY2028 Earnings - MarketBeat
If You Invested $1,000 in Editas Medicine Inc (EDIT) - Stock Titan
Editas Medicine, Inc. Trade Ideas — LS:A2AC4K - TradingView
RSI Check: Can Editas Medicine Inc outperform in the next rally2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
Institution Moves: Can Editas Medicine Inc disrupt its industry2026 News Drivers & Technical Pattern Based Buy Signals - baoquankhu1.vn
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline ChallengesNews and Statistics - IndexBox
Is Editas Medicine Going to $0? - The Globe and Mail
Can Editas Medicine Inc grow without external funding2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH) - The Globe and Mail
Is Editas Medicine Headed Toward Zero? - Bitget
Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer - Stock Titan
Editas Medicine (EDIT) CEO awarded 1.02M stock options vesting over 4 years - Stock Titan
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 - MarketBeat
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com Canada
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects - TipRanks
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad - GuruFocus
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading - MarketBeat
Jones Trading upgrades Editas Medicine stock rating on gene therapy progress - Investing.com Canada
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.76%
0.79%
자본화:
|
볼륨(24시간):